Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Price Target from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $14.20.

Several brokerages have weighed in on AMRX. Truist Financial lifted their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Barclays began coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of AMRX. Vanguard Group Inc. grew its stake in Amneal Pharmaceuticals by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock valued at $179,729,000 after acquiring an additional 403,582 shares during the last quarter. Rubric Capital Management LP grew its position in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amneal Pharmaceuticals by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock valued at $70,681,000 after purchasing an additional 177,906 shares during the last quarter. Morgan Stanley raised its position in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $12.11 on Tuesday. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $15.42. The firm has a 50-day simple moving average of $13.80 and a 200-day simple moving average of $11.96. The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of 52.65 and a beta of 1.35.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.